◆ 会议时间：2024年9月7-11日
◆ 会议地点：意大利 罗马

◆ 会议简介：

2024年第15届欧洲癫痫病学大会将于2024年9月7-11日在意大利罗马举行，本次大会由国际抗癫痫联盟(ILAE)主办。

国际抗癫痫联盟(ILAE)成立于1909年，是一个拥有100多个国家分会的全球性组织，其宗旨是促进和传播有关癫痫的知识；促进研究、教育和培训；特别是通过预防、诊断和治疗，改善对患者的宣服务和护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

EEC 2024 - 15th European Epilepsy Congress

Date: 7 - 11 September 2024
Venue: Roma Convention Center La Nuvola, Rome, Italy

摘要征文投稿：

Abstracts

Deadline for submission 2 February 2024

点此提交摘要>>>Submit Abstract>>>

Maximum word count is 300.

Abstract Submission Rules

1. Abstracts will not be accepted unless they are submitted online via the online abstract submission system before midnight (GMT) on the deadline date. Abstracts received after this date will NOT be accepted. Abstracts submitted by post, fax or email will NOT be considered.
2. All abstracts should be written, submitted and presented in English with a maximum word count of 300 words (not including the abstract title, authors and institutions).
3. Authors will be notified in writing as to whether or not their abstract has been accepted by the Abstract Review Committee. The decision of the committee is final and no correspondence will be entered into.
4. Once an abstract has been accepted, the presenting author must register for the congress for final acceptance. An abstract presenter may not register as a day delegate.
5. Abstracts accepted and presented at the congress will be listed on the congress website. Subject to editorial review, abstracts may be published in a supplement to Epilepsia.
6. The abstracts of authors who do not register for the congress will be excluded from publication.
7. Instructions for both platform and e-poster presentations will be available on the congress website. Authors selected for oral presentations should use Microsoft PowerPoint only (PC format).
8. All correspondence will be sent to the submitting author only. It is the responsibility of the submitting author to forward any relevant correspondence to the presenting author.

Abstract Content Rules

1. Abstract submitters should ensure that the final version is submitted by the deadline; changes will not be permitted once the deadline has passed.
2. Institution information should be provided for all authors. Please include institution, city, state/ province and country but exclude department, division, laboratory, etc.
3. A topic category for each abstract must be selected during the submission process.
4. Abstracts should be structured in 4 sections as follows:

• Purpose: Should indicate the objectives of the work being presented.
• Method: Should describe study material or subjects (e.g. number and type of patients), intervention and evaluation procedures.
• Results: Should summarize the main findings. Wherever possible, give numerical values, including means with SD or SEM, and statistical significance or confidence intervals.
• Conclusion: Should state briefly the conclusions reached in the work.

5. Figures, tables and other illustrations may not be included.
6. If the work was supported by funds provided by a commercial organisation this should be stated in a short acknowledgment at the end of the abstract. Other sources of funding may be acknowledged in the same way.
7. Submission of multiple abstracts describing different components of the same study is not appropriate. All findings generated from the same study should be included in a single abstract.
8. Abstracts containing single case reports will not usually be accepted, unless the report is of outstanding scientific or clinical interest because of the uniqueness of the findings or the sophistication of the investigations.
9. Abstracts containing data considered to be insufficiently informative will not be accepted.
10. Authors should use a concise title that indicates the content of the abstract. Abbreviations should be avoided in the title.
11. For intervention studies (for example, therapeutic trials), type of design (prospective or retrospective, controlled or uncontrolled, randomized or observational, open vs. single-blind vs. double-blind), dosages, assessment methods and duration of follow-up should be specified.
12. Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.
13. Abbreviations should be used sparingly. For words that are abbreviated, use the whole term the first time, followed by the standard abbreviation in parenthesis.
14. References should be used sparingly. They should be included within the text in brackets. For journals, mention first author “et al”, followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages (e.g. Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author “et al”, editor, title, publisher, city of publication, year and inclusive pages (e.g. Levy RH et al. In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.).
15. Submission of an abstract automatically implies acknowledgment that the work described was conducted in accordance with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in rejection of the abstract.

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。